01
Cash & equivalents decreased 4.6%
Cash & equivalents changed -4.6% from the comparable as-filed period.
$17.8M→$17.0MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAllarity Therapeutics, Inc.'s latest supported as-filed period reports net income of -$3.4M, 46.8% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -4.6% from the comparable as-filed period.
Net income changed -46.8% from the comparable as-filed period.
Operating income changed +35.4% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ALLR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-090183SEC ↗10-QAug 14, 2026Period Jun 30, 20260001437749-26-027830SEC ↗8-KJul 1, 2026Period Jun 26, 20260001213900-26-073998SEC ↗8-KJun 22, 2026Period Jun 18, 20260001213900-26-070382SEC ↗8-KJun 2, 2026Period May 27, 20260001213900-26-064278SEC ↗10-QMay 15, 2026Period Mar 31, 20260001437749-26-017371SEC ↗4May 14, 2026Period Jan 28, 20260001213900-26-056373SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jan 28, 2026Filed May 14, 2026 | Jensen ThomasCEO | Grant Or AwardDirect | 200,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -42.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +14.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-054430